mRNA-1468, Shingrix — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468
Phase 1/2 · Herpes Zoster |
ModernaTX, Inc. | mRNA-1468, Shingrix |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|